Glyx 13 News

Possible release in 2019?

chicagotribune.com/bluesky/originals/chi-naurex-series-c-funding-bsi-20141202-story.html

REPLY

REPORT

@citygirl,

Thanks for sharing this article on the advancement of GLYX-13. I think as long as Evanston can continue to utilize this molecule while minimizing the types of side effects that plague most prescription drugs, they'd find much success expanding on it's application for depression.

The research backing up their experiments gives hope to those with treatment resistant depression and in my opinion may be a viable alternative for patients seeking a safer approach to managing these symptoms in the long run.

I'll be looking forward to more updates as things progress!

REPLY

Was this helpful? 1

I meant to share this blurb from Chicago Magazine, as well. I have completed 20 treatments and am doing better than I have in several years. My response was NOT immediate but took over a month of weekly treatments. I am not near 100 percent, but am doing substantively better.

The Fast-Acting Antidepressant

It seems like some horribly cruel joke. There’s no shortage of medications to help people escape the dark spiral of depression, yet the drugs all come with a catch: They take an agonizingly long time—up to six weeks—to kick in.

But that delay could eventually be a thing of the past. A new compound called GLYX-13 (GLYX is pronounced “glicks”) developed by a Chicago-area scientist is producing results within a mere 24 hours in human trials. Just as notable: The medication has displayed none of the side effects common in antidepressants, such as headaches, nausea, and lowered libido.

So how did such a drug come to be? Its creator, Joseph Moskal, gets almost poetic in answering. “A big part of what it means to be human is to be able to think, learn, remember, forget, get depressed, get excited, be happy, and fall in love,” says the founder and chief scientific officer of the six-year-old Evanston-based biopharmaceutical company Naurex. “They’re all connected, so by looking at how the brain makes and breaks memories and learns, there were keys to how to inhibit things like depression.”

Prozac and other common antidepressants keep levels of serotonin, a crucial brain chemical, high by preventing its reabsorption. GLYX-13 works on a different neurotransmitter, glutamate, which some believe affects depression more directly—hence the quick results. “We’re bringing the whole business of how the brain functions to bear,” says Moskal, who is also a research professor at Northwestern University and serves as director of its Falk Center for Molecular Therapeutics. GLYX-13 allows the levels of glutamate to be fine-tuned—somewhat the way a thermostat “can very, very exquisitely, very precisely, control the room’s temperature.” (Other biotechs are working on developing fast-acting antidepressants—ones that enlist compounds similar to the drug ketamine—but those can cause symptoms of psychosis, according to medical journals.)

Moskal, who hopes to have GLYX-13 on the market within a few years, notes that this application could be just the start when it comes to treating neuropsychiatric disorders. “These receptors have a big role in lots of things that can go wrong,” he says. “People with bipolar disorder, obsessive-compulsive disorder, schizophrenia, posttraumatic stress disorder, and traumatic brain injury could all possibly benefit from the discovery. It’s a very exciting time.”

REPLY

Was this helpful? 2

Very insightful information citygirl!

I'm glad to hear that your progress has been substantial. In the midst of depression, this is a great feat!

Understanding how the brain works in response to certain compounds like Mr. Moskal has, will undoubtedly bring depression medication to a new level. Unlike common antidepressants such as Prozac and Amitriptyline that are ridden with side effects, Glyx-13 sounds like it would be a breath of fresh air in comparison.

Thank you for keeping the community informed about its research!

REPLY

Was this helpful? 1

There seems to be some demand for a GLYX-13 discussion (now known as Rapastinel) so I would like to start one here. ## G...

111 REPLIES

Any idea as to when they are going to start Phase III of the trials on GLYX13? ## I know there have been some recent stu...

3 REPLIES

GLYX-13 open label study is now scheduled to begin in June, according to my local study center. I will update as I get m...

2 REPLIES

I have completed 13 treatments and while I never felt any "immediate" effect, I have been doing increasingly bet...

3 REPLIES

Anyone heard if the generic 80ER MG. Is coming back in January of 2014?I can't find any news on it.Please reply. I&#...

9 REPLIES

I just saw this. FDA rejects Endo's deadline. Generic Opana will be produced but could change again in May 2013 The ...

7 REPLIES

Amphastar, the maker of the discontinued Primatene Mist, says on their website that a reformulated Primatene Mist is com...

1 REPLY

ordered polyy cernol no risk trial,15day trial +60 day supply @£24.99 every month+free gift radio,15 day arrived no...

1 REPLY

I just saw this on the news. They were talking about the drug Fentanyl and that it's deadly just to touch it. It had...

1 REPLY

I suffer from fibromyalgia (for years) amungst other muscle and joint diseases, and have always taken Lyrica, which has ...

4 REPLIES